Skip to main content
Retour
Watch Compare

Nasus Pharma Ltd

Qualité des données : 100%
NSRX
NYSE Manufacturing Chemicals
2,26 €
▼ 0,08 € (-3,42%)
Cap. Boursière: 26,47 M
Prix
2,26 €
Cap. Boursière
26,47 M
Fourchette du Jour
2,25 € — 2,36 €
Fourchette 52 Semaines
1,98 € — 9,99 €
Volume
16 404
Ouverture 2,32 €
Moyenne 50J / 200J
4,48 €
49,56% below
Moyenne 50J / 200J
6,57 €
65,61% below

Quick Summary

Points Clés

Negative free cash flow of -4,93 M
Capital efficient — spends only 0,00% of revenue on capex

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-211,56%
En dessous de la moyenne du secteur (-53,47%)
ROIC-136,37%
Net Margin-0,47%
Op. Margin-0,40%

Sécurité

Debt / Equity
N/A
Current Ratio0,06
Interest Coverage-62,87

Valorisation

PE (TTM)
-4,52
En dessous de la moyenne du secteur (-1,47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -4,5 -1,5
P/B — 1,6
ROE % -211,6 -53,5
Net Margin % -0,5 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,24 B Net Income (TTM) -5,86 M
ROE -211,56% ROA -117,03%
Gross Margin N/A Operating Margin -0,40%
Net Margin -0,47% Free Cash Flow (TTM) -4,93 M
ROIC -136,37% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,06
Interest Coverage -62,87 Asset Turnover 246,80
Working Capital -4,66 M Tangible Book Value -4,31 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4,52 Forward P/E N/A
P/B Ratio N/A P/S Ratio 0,02
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -18,63%
Market Cap 26,47 M Enterprise Value 26,26 M
Per Share
EPS (Diluted TTM) -0,72 Revenue / Share 105,46
FCF / Share -0,42 OCF / Share -0,42
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,00% FCF Conversion 84,22%
SBC-Adj. FCF -5,38 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025
Revenue 1,24 B
Net Income -5,86 M
EPS (Diluted) -0,72
Gross Profit —
Operating Income -4,90 M
EBITDA —
R&D Expenses 2,24 M
SG&A Expenses —
D&A —
Interest Expense -78 000,0
Income Tax —

Balance Sheet

Annual, most recent first
Metric FY2025
Total Assets 5,00 M
Total Liabilities 2,24 M
Shareholders' Equity 2,77 M
Total Debt —
Cash & Equivalents 1,24 M
Current Assets 4,86 M
Current Liabilities 2,16 M